Commonwealth Consolidated Regulations

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1960 - REG 37J

         (1)   For paragraph 99ADC (1) (c) of the Act, the information mentioned in regulation 37H must be provided within 6 weeks after the end of each reporting period for the brand of the pharmaceutical item.

         (2)   Subject to subregulations (3) to (6) and regulation 37JA, a reporting period for a brand of a pharmaceutical item is:

                (a)    the period of 6 months ending at the end of 31 March of each year and 30 September of each year; and

               (b)    each successive period of 6 months in which the brand is subject to the price disclosure requirements.

         (3)   However, the first reporting period for a relevant brand to which regulation 37ED applies:

                (a)    begins on the relevant day mentioned in regulation 37ED for the relevant brand; and

               (b)    ends at the end of the first of the following dates to happen after the relevant day:

                          (i)    31 March;

                         (ii)    30 September.

         (4)   Also, the first reporting period for a relevant brand in the relevant disclosure cycle mentioned in regulation 37F to which that regulation applies:

                (a)    begins on the relevant day mentioned in regulation 37F; and

               (b)    ends at the end of:

                          (i)    if the other brand mentioned in regulation 37F is in the interim supplementary disclosure cycle or a supplementary disclosure cycle A or supplementary disclosure cycle B -- the reporting period for the other brand; or

                         (ii)    in any other case -- the first of the following dates to happen after the relevant day:

                                   (A)     31 March;

                                   (B)     30 September.

         (5)   Also, the first reporting period in the data collection period in the first main disclosure cycle for a brand of a pharmaceutical item to which regulation 37EG applies:

                (a)    begins on 1 February in the year the brand moves to the main disclosure cycle; and

               (b)    ends at the end of 31 March in the year.

         (6)   Also, the first reporting period in the data collection period in the first main disclosure cycle for a brand of a pharmaceutical item to which regulation 37EH applies:

                (a)    begins on 1 June in the year the brand moves to the main disclosure cycle; and

               (b)    ends at the end of 30 September in the year.

Note    For transitional arrangements, see Part 2 of the National Health (Pharmaceutical Benefits) Amendment Regulations 2010 (No. 5).